Article
Neurosciences
Xi Chen, Jinli Sun, Yukui Li, Weichao Jiang, Zhangyu Li, Jianyao Mao, Liwei Zhou, Sifang Chen, Guowei Tan
Summary: This study combines metabolomics and proteomics to investigate the methylation mechanism in glioblastoma and identifies prognostic biomarkers for two different types of GBM.
CNS NEUROSCIENCE & THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Katja Werlenius, Sara Kinhult, Tora Skeidsvoll Solheim, Henriette Magelssen, David Loefgren, Munila Mudaisi, Sofia Hylin, Jiri Bartek, Michael Strandeus, Magnus Lindskog, Havyan Bahroz Rashid, Louise Carstam, Sasha Gulati, Ole Solheim, Jiri Bartek, Oyvind Salvesen, Asgeir Store Jakola
Summary: In patients with recurrent glioblastoma, the addition of disulfiram and copper to chemotherapy resulted in significantly increased toxic effects, but no significant difference in survival, according to this multicenter, open-label, randomized phase II/III clinical trial. These findings suggest that disulfiram and copper is without benefit in patients with recurrent glioblastoma.
Article
Oncology
Ashly Hindle, Balakrishna Koneru, Monish Ram Makena, Lluis Lopez-Barcons, Wan Hsi Chen, Thinh H. Nguyen, C. Patrick Reynolds
Summary: High MGMT expression is associated with resistance to alkylating agents and TMZ+IRN in preclinical neuroblastoma models. The MGMT inhibitor O6BG enhances the anticancer effect of TMZ+IRN in vitro and in vivo.
Article
Biology
Sanjay Saxena, Biswajit Jena, Bibhabasu Mohapatra, Neha Gupta, Manudeep Kalra, Mario Scartozzi, Luca Saba, Jasjit S. Suri
Summary: This study used multi-parametric MRI and machine learning methods to analyze the treatment plan for glioblastoma and developed a predictive model for MGMT methylation biomarkers.
COMPUTERS IN BIOLOGY AND MEDICINE
(2023)
Article
Cell Biology
Lucia Cannella, Rosa Della Monica, Antonella Lucia Marretta, Domenico Iervolino, Bruno Vincenzi, Anna Rosaria De Chiara, Ottavia Clemente, Michela Buonaiuto, Maria Luisa Barretta, Annabella Di Mauro, Massimiliano Di Marzo, Michele Guida, Giuseppe Badalamenti, Lorenzo Chiariotti, Salvatore Tafuto
Summary: This retrospective study investigated the correlation between the methylation status of the MGMT promoter and clinical outcomes of dacarbazine-treated patients with leiomyosarcoma (LMS). The results showed better outcomes in patients with unmethylated MGMT, indicating a relationship between MGMT methylation and poor prognosis in LMS.
Article
Biochemistry & Molecular Biology
Shao-Wei Feng, Pei-Chi Chang, Hsuan-Yu Chen, Dueng-Yuan Hueng, Yao-Feng Li, Shih-Ming Huang
Summary: Metformin has been shown to effectively reduce cell proliferation and migration, promote cell apoptosis, and disrupt mitochondrial metabolism in glioblastoma cells. Additionally, the combination treatment of metformin and temozolomide has different effects on glioblastoma cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Stephanie Lheureux, Mihaela C. Cristea, Jeffrey P. Bruce, Swati Garg, Michael Cabanero, Gina Mantia-Smaldone, Alexander B. Olawaiye, Susan L. Ellard, Johanne I. Weberpals, Andrea E. Wahner Hendrickson, Gini F. Fleming, Stephen Welch, Neesha C. Dhani, Tracy Stockley, Prisni Rath, Katherine Karakasis, Gemma N. Jones, Suzanne Jenkins, Jaime Rodriguez-Canales, Michael Tracy, Qian Tan, Valerie Bowering, Smitha Udagani, Lisa Wang, Charles A. Kunos, Eric Chen, Trevor J. Pugh, Amit M. Oza
Summary: The study aimed to evaluate the efficacy of the Weel inhibitor adavosertib and gemcitabine in patients with ovarian cancer. The combination therapy showed longer progression-free survival in high-grade serous ovarian cancer patients compared to gemcitabine alone, supporting further assessment of DNA damage response drugs in this tumor type.
Article
Oncology
Adomas Bunevicius, Stylianos Pikis, Douglas Kondziolka, Dev N. Patel, Kenneth Bernstein, Erik P. Sulman, Cheng-chia Lee, Huai-che Yang, Violaine Delabar, David Mathieu, Christopher P. Cifarelli, David E. Arsanious, Basem A. Dahshan, Joshua S. Weir, Herwin Speckter, Angel Mota, Manjul Tripathi, Narendra Kumar, Ronald E. Warnick, Selcuk Peker, Yavuz Samanci, Gene Barnett, Farid El Hefnawi, Ghusn Al Sideiri, Jason Sheehan
Summary: SRS prescription dose of > 14 Gy is associated with longer progression free survival while tumor volume of > 5 cc is associated with shorter overall survival after SRS for IDH-wt glioblastomas. Adverse radiation events (AREs) are rare and are typically managed conservatively.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Article
Clinical Neurology
Adomas Bunevicius, Stylianos Pikis, Douglas Kondziolka, Dev N. Patel, Kenneth Bernstein, Erik P. Sulman, Cheng-chia Lee, Huai-che Yang, Violaine Delabar, David Mathieu, Christopher P. Cifarelli, David E. Arsanious, Basem A. Dahshan, Joshua S. Weir, Herwin Speckter, Angel Mota, Manjul Tripathi, Narendra Kumar, Ronald E. Warnick, Jason P. Sheehan
Summary: Molecular profiles, such as IDH mutation and MGMT methylation status, play important prognostic roles for glioblastoma patients. Post-SRS survival was similar regardless of IDH mutation and MGMT promoter methylation status, suggesting the importance of considering molecular profiles when selecting candidates for SRS.
JOURNAL OF NEUROSURGERY
(2021)
Review
Oncology
P. Trillo Aliaga, F. Spada, G. Peveri, V. Bagnardi, C. Fumagalli, A. Laffi, M. Rubino, L. Gervaso, E. Guerini Rocco, E. Pisa, G. Curigliano, N. Fazio
Summary: The meta-analysis suggested that MGMT status may predict the efficacy of TEM in NETs patients. Patients with MGMT deficiency showed better response rate, progression free survival, and overall survival compared to those with MGMT proficiency.
CANCER TREATMENT REVIEWS
(2021)
Article
Biotechnology & Applied Microbiology
R. J. A. Vibhavari, Vanishree Rao, Sri Pragnya Cheruku, B. Harish Kumar, Swastika Maity, Krishnadas Nandakumar, Lalit Kumar, Chetan Hasmukh Mehta, Usha Nayak, Mallikarjuna Rao Chamallamudi, Nitesh Kumar
Summary: The aim of this study was to investigate the potential of phytochemicals, including rutin, catechin, dehydrozingerone, naringenin, and quercetin, either alone or in combination with temozolomide, to inhibit the expression of MGMT in glioma cells. The results showed that the combination of quercetin and temozolomide effectively reduced temozolomide resistance and could serve as a potential therapeutic target for glioblastoma treatment.
Review
Medicine, General & Internal
Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L. Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P. T. Higgins, Kathreena M. Kurian
Summary: This study focuses on determining the most accurate method for assessing MGMT methylation status in patients with glioblastoma treated with temozolomide. Results show that MSP and PSQ methods are more prognostic for overall survival than IHC. It suggests that PSQ may be slightly more prognostic than MSP, and targeted multiple CpG sites may be more effective than targeting just one.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Review
Oncology
Francesco Pasqualetti, Alessandro Barberis, Sofia Zanotti, Nicola Montemurro, Gian Luca De Salvo, Riccardo Soffietti, Chiara Maria Mazzanti, Tamara Ius, Maria Caffo, Fabiola Paiar, Guido Bocci, Giuseppe Lombardi, Adrian L. Harris, Francesca M. Buffa
Summary: Despite advances in CNS malignancies therapy, GB treatment remains challenging due to resistance and high recurrence rates. Most predictive GB biomarkers are developed using surgical samples, but selection criteria vary among neurosurgeons, making the patients not representative. Survivorship bias affects biomarkers for patient selection, therapy, and outcome analyses.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Yue-Xia Chen, Lu-Lu He, Xue-Ping Xiang, Jing Shen, Hong-Yan Qi
Summary: The aim of this study was to investigate the molecular regulatory mechanism of MGMT in NOCs-induced gastric cell malignant transformation and tumorigenesis. The results found that the upregulation of MGMT was induced through DNA promoter hypomethylation. The highly expressed MGMT prevented the NOCs-induced cell malignant transformation and tumorigenesis.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2022)
Article
Oncology
Shukui Qin, Zhendong Chen, Weijia Fang, Zhenggang Ren, Ruocai Xu, Baek-Yeol Ryoo, Zhiqiang Meng, Yuxian Bai, Xiaoming Chen, Xiufeng Liu, Juxiang Xiao, Gwo Fuang Ho, Yimin Mao, Xin Wang, Jieer Ying, Jianfeng Li, Wenyan Zhong, Yu Zhou, Abby B. Siegel, Chunyi Hao
Summary: Pembrolizumab significantly prolonged overall survival and progression-free survival in previously treated advanced hepatocellular carcinoma patients from Asia, with a higher objective response rate compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg
Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.
Article
Oncology
Philipp Vollmuth, Martha Foltyn, Raymond Y. Huang, Norbert Galldiks, Jens Petersen, Fabian Isensee, Martin J. van den Bent, Frederik Barkhof, Ji Eun Park, Yae Won Park, Sung Soo Ahn, Gianluca Brugnara, Hagen Meredig, Rajan Jain, Marion Smits, Whitney B. Pope, Klaus Maier-Hein, Michael Weller, Patrick Y. Wen, Wolfgang Wick, Martin Bendszus
Summary: This study aimed to assess the reproducibility and standardization of treatment response assessment using artificial intelligence (AI) decision support in MRI. The results showed that AI decision support can provide better evaluation of treatment response in patients with lower-grade gliomas compared to manual measurements.
Article
Oncology
Marta Espanol-Rego, Carlos Fernandez-Martos, Elena Elez, Carles Foguet, Leire Pedrosa, Nuria Rodriguez, Ana Ruiz-Casado, Estela Pineda, Joan Cid, Raquel Cabezon, Helena Oliveres, Miquel Lozano, Angels Gines, Angeles Garcia-Criado, Juan Ramon Ayuso, Mario Pages, Miriam Cuatrecasas, Ferran Torres, Timothy Thomson, Marta Cascante, Daniel Benitez-Ribas, Joan Maurel
Summary: This study investigated the potential of Avelumab combined with ADC vaccine as a treatment for MSS mCRC patients. The results showed that the combination therapy was safe and well tolerated, but had limited clinical activity. Additionally, the study found a post-therapy metabolic rewiring, which could represent novel immunotherapy-induced tumor vulnerabilities.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Sied Kebir, Vivien Ullrich, Pia Berger, Celia Dobersalske, Sarah Langer, Laurel Rauschenbach, Daniel Trageser, Andreas Till, Franziska K. Lorbeer, Anja Wieland, Timo Wilhelm-Buchstab, Ashar Ahmad, Holger Froehlich, Igor Cima, Shruthi Prasad, Johann Matschke, Verena Jendrossek, Marc Remke, Barbara M. Gruener, Alexander Roesch, Jens T. Siveke, Christel Herold-Mende, Tobias Blau, Kathy Keyvani, Frank K. H. van Landeghem, Torsten Pietsch, Jorg Felsberg, Guido Reifenberger, Michael Weller, Ulrich Sure, Oliver Bruestle, Matthias Simon, Martin Glas, Bjoern Scheffler
Summary: This study aimed to identify and target tumor cells that can survive, adapt, and expand under primary therapy in glioblastoma. The researchers found that ALDH1A1+/pAKT+ subclones accumulate and acquire drug resistance in response to temozolomide treatment. They propose a combination therapy of temozolomide and AKT inhibitors as a potential treatment strategy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller
Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Julie J. Miller, L. Nicolas Gonzalez Castro, Samuel McBrayer, Michael Weller, Timothy Cloughesy, Jana Portnow, Ovidiu Andronesi, Jill S. Barnholtz-Sloan, Brigitta G. Baumert, Mitchell S. Berger, Wenya Linda Bi, Ranjit Bindra, Daniel P. Cahill, Susan M. Chang, Joseph F. Costello, Craig Horbinski, Raymond Y. Huang, Robert B. Jenkins, Keith L. Ligon, Ingo K. Mellinghoff, L. Burt Nabors, Michael Platten, David A. Reardon, Diana D. Shi, David Schiff, Wolfgang Wick, Hai Yan, Andreas von Deimling, Martin van den Bent, William G. Kaelin, Patrick Y. Wen
Summary: This article discusses the diagnosis and management of IDH-mutant gliomas, as well as new treatment methods and future research directions.
Article
Clinical Neurology
Katharina Seystahl, Juliane Schweizer, Mira Katan, Sung Ju Weber, Alessia Hug, Miriam Wanner, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
Summary: Cancer is not a risk factor for stroke-associated infections in stroke patients. The incidence, characteristics, and treatment of infections did not differ significantly between stroke patients with and without cancer. However, both cancer and stroke-associated infections were associated with in-hospital mortality.
NEURO-ONCOLOGY PRACTICE
(2023)
Article
Oncology
Anna M. Di Giacomo, Maximilian J. Mair, Michele Ceccarelli, Andrea Anichini, Ramy Ibrahim, Michael Weller, Michael Lahn, Alexander M. M. Eggermont, Bernard Fox, Michele Maio
Summary: The conditions that promote immunotherapy responses in primary or secondary brain malignancies were discussed during the V Siena Immuno-Oncology (IO) Think Tank meeting in 2021. Important publications in 2021 and 2022 have reinforced the core elements of these discussions. While current immunotherapies have failed to benefit patients with primary brain tumors like glioblastoma, they have shown positive responses in brain metastases. The differences between these conditions seem to be influenced by intrinsic and extrinsic factors, such as driver mutations, the blood-brain barrier, and the immune suppressive microenvironment. Future therapeutic interventions may focus on rebalancing the immune cell population to enable better responses to current and future immunotherapies.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Corinna Seliger, Felix Boakye Oppong, Florence Lefranc, Olivier Chinot, Roger Stupp, Burt Nabors, Thierry Gorlia, Michael Weller, EORTC Brain Tumor Group
Summary: Depressive symptoms are common in glioblastoma patients, but they are often not treated with antidepressants. Limited evidence suggests that the use of antidepressants is not significantly associated with progression-free or overall survival in glioblastoma patients. However, using antidepressants at the start of maintenance cycle 4 is significantly associated with worse overall survival. Antidepressant use is not significantly associated with seizures, cognitive changes, or fatigue, except for an increase in fatigue during maintenance treatment. Confirmation and further study are needed to assess the impact of antidepressant use on the survival of glioblastoma patients. Prospective trials should evaluate the efficacy, side effects, and outcomes of antidepressant treatment in glioblastoma.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Evelina Blomberg, Manuela Silginer, Patrick Roth, Michael Weller
Summary: Despite various treatment approaches, the survival rate for glioblastoma patients remains low. This study implicates that constitutive type I interferon signaling in gliomas may promote tumor growth, but only in a microenvironment with a proficient type I interferon signaling in the host.
TRANSLATIONAL ONCOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Estela Pineda, Marta Domenech, Ainhoa Hernandez, Silvia Comas, Carmen Balana
Summary: Treating glioblastomas is challenging and there are currently no effective alternative treatments. The main difficulties in treatment arise from the low incidence of the disease, age and neurological symptoms of patients, and issues related to the drugs themselves.
ONCOTARGETS AND THERAPY
(2023)
Correction
Multidisciplinary Sciences
Sarthak Pati, Ujjwal Baid, Brandon Edwards, Micah Sheller, Shih-Han Wang, G. Anthony Reina, Patrick Foley, Alexey Gruzdev, Deepthi Karkada, Christos Davatzikos, Chiharu Sako, Satyam Ghodasara, Michel Bilello, Suyash Mohan, Philipp Vollmuth, Gianluca Brugnara, Chandrakanth J. Preetha, Felix Sahm, Klaus Maier-Hein, Maximilian Zenk, Martin Bendszus, Wolfgang Wick, Evan Calabrese, Jeffrey Rudie, Javier Villanueva-Meyer, Soonmee Cha, Madhura Ingalhalikar, Manali Jadhav, Umang Pandey, Jitender Saini, John Garrett, Matthew Larson, Robert Jeraj, Stuart Currie, Russell Frood, Kavi Fatania, Raymond Y. Huang, Ken Chang, Carmen Balana, Jaume Capellades, Josep Puig, Johannes Trenkler, Josef Pichler, Georg Necker, Andreas Haunschmidt, Stephan Meckel, Gaurav Shukla, Spencer Liem, Gregory S. Alexander, Joseph Lombardo, Joshua D. Palmer, Adam E. Flanders, Adam P. Dicker, Haris I. Sair, Craig K. Jones, Archana Venkataraman, Meirui Jiang, Tiffany Y. So, Cheng Chen, Pheng Ann Heng, Qi Dou, Michal Kozubek, Filip Lux, Jan Michalek, Petr Matula, Milos Kerkovsky, Tereza Koprivova, Marek Dostal, Vaclav Vybihal, Michael A. Vogelbaum, J. Ross Mitchell, Joaquim Farinhas, Joseph A. Maldjian, Chandan Ganesh Bangalore Yogananda, Marco C. Pinho, Divya Reddy, James Holcomb, Benjamin C. Wagner, Benjamin M. Ellingson, Timothy F. Cloughesy, Catalina Raymond, Talia Oughourlian, Akifumi Hagiwara, Chencai Wang, Minh-Son To, Sargam Bhardwaj, Chee Chong, Marc Agzarian, Alexandre Xavier Falcao, Samuel B. Martins, Bernardo C. A. Teixeira, Flavia Sprenger, David Menotti, Diego R. Lucio, Pamela LaMontagne, Daniel Marcus, Benedikt Wiestler, Florian Kofler, Ivan Ezhov, Marie Metz, Rajan Jain, Matthew Lee, Yvonne W. Lui, Richard McKinley, Johannes Slotboom, Piotr Radojewski, Raphael Meier, Roland Wiest, Derrick Murcia, Eric Fu, Rourke Haas, John Thompson, David Ryan Ormond, Chaitra Badve, Andrew E. Sloan, Vachan Vadmal, Kristin Waite, Rivka R. Colen, Linmin Pei, Murat Ak, Ashok Srinivasan, J. Rajiv Bapuraj, Arvind Rao, Nicholas Wang, Ota Yoshiaki, Toshio Moritani, Sevcan Turk, Joonsang Lee, Snehal Prabhudesai, Fanny Moron, Jacob Mandel, Konstantinos Kamnitsas, Ben Glocker, Luke V. M. Dixon, Matthew Williams, Peter Zampakis, Vasileios Panagiotopoulos, Panagiotis Tsiganos, Sotiris Alexiou, Ilias Haliassos, Evangelia I. Zacharaki, Konstantinos Moustakas, Christina Kalogeropoulou, Dimitrios M. Kardamakis, Yoon Seong Choi, Seung-Koo Lee, Jong Hee Chang, Sung Soo Ahn, Bing Luo, Laila Poisson, Ning Wen, Pallavi Tiwari, Ruchika Verma, Rohan Bareja, Ipsa Yadav, Jonathan Chen, Neeraj Kumar, Marion Smits, Sebastian R. van der Voort, Ahmed Alafandi, Fatih Incekara, Maarten M. J. Wijnenga, Georgios Kapsas, Renske Gahrmann, Joost W. Schouten, Hendrikus J. Dubbink, Arnaud J. P. E. Vincent, Martin J. van den Bent, Pim J. French, Stefan Klein, Yading Yuan, Sonam Sharma, Tzu-Chi Tseng, Saba Adabi, Simone P. Niclou, Olivier Keunen, Ann-Christin Hau, Martin Vallieres, David Fortin, Martin Lepage, Bennett Landman, Karthik Ramadass, Kaiwen Xu, Silky Chotai, Lola B. Chambless, Akshitkumar Mistry, Reid C. Thompson, Yuriy Gusev, Krithika Bhuvaneshwar, Anousheh Sayah, Camelia Bencheqroun, Anas Belouali, Subha Madhavan, Thomas C. Booth, Alysha Chelliah, Marc Modat, Haris Shuaib, Carmen Dragos, Aly Abayazeed, Kenneth Kolodziej, Michael Hill, Ahmed Abbassy, Shady Gamal, Mahmoud Mekhaimar, Mohamed Qayati, Mauricio Reyes, Ji Eun Park, Jihye Yun, Ho Sung Kim, Abhishek Mahajan, Mark Muzi, Sean Benson, Regina G. H. Beets-Tan, Jonas Teuwen, Alejandro Herrera-Trujillo, Maria Trujillo, William Escobar, Ana Abello, Jose Bernal, Jhon Gomez, Joseph Choi, Stephen Baek, Yusung Kim, Heba Ismael, Bryan Allen, John M. Buatti, Aikaterini Kotrotsou, Hongwei Li, Tobias Weiss, Michael Weller, Andrea Bink, Bertrand Pouymayou, Hassan F. Shaykh, Joel Saltz, Prateek Prasanna, Sampurna Shrestha, Kartik M. Mani, David Payne, Tahsin Kurc, Enrique Pelaez, Heydy Franco-Maldonado, Francis Loayza, Sebastian Quevedo, Pamela Guevara, Esteban Torche, Cristobal Mendoza, Franco Vera, Elvis Rios, Eduardo Lopez, Sergio A. Velastin, Godwin Ogbole, Mayowa Soneye, Dotun Oyekunle, Olubunmi Odafe-Oyibotha, Babatunde Osobu, Mustapha Shu'aibu, Adeleye Dorcas, Farouk Dako, Amber L. Simpson, Mohammad Hamghalam, Jacob J. Peoples, Ricky Hu, Anh Tran, Danielle Cutler, Fabio Y. Moraes, Michael A. Boss, James Gimpel, Deepak Kattil Veettil, Kendall Schmidt, Brian Bialecki, Sailaja Marella, Cynthia Price, Lisa Cimino, Charles Apgar, Prashant Shah, Bjoern Menze, Jill S. Barnholtz-Sloan, Jason Martin, Spyridon Bakas
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Katharina Seystahl, Dorothee Gramatzki, Miriam Wanner, Sung Ju Weber, Alessia Hug, Andreas R. Luft, Sabine Rohrmann, Susanne Wegener, Michael Weller
Summary: The occurrence of cancer in stroke patients can be associated with elevated levels of white blood cells, platelets, and d-dimers. Additionally, the presence of ischemic lesions in multiple vascular territories is also linked to cancer diagnosis within one year after stroke.
SCIENTIFIC REPORTS
(2023)
Article
Cell Biology
Neus Martinez-Bosch, Noelia Vilarino, Francesc Alameda, Sergi Mojal, Montserrat Arumi-Uria, Cristina Carrato, Iban Aldecoa, Teresa Ribalta, Noemi Vidal, Beatriz Bellosillo, Silvia Menendez, Sonia Del Barco, Oscar Gallego, Estela Pineda, Raquel Lopez-Martos, Ainhoa Hernandez, Carlos Mesia, Anna Esteve-Codina, Nuria de la Iglesia, Carme Balana, Maria Martinez-Garcia, Pilar Navarro
Summary: Glioblastoma (GBM) is a primary malignant brain tumor with a poor prognosis. Immune checkpoint inhibitors have not been effective in GBM patients, so there is a need for new treatment targets and biomarkers. Galectin-1 (Gal-1) is a protein with pro-tumor functions and its expression was evaluated in GBM patients. Higher levels of Gal-1 were found in the more aggressive subtypes of GBM and correlated with immune suppressive signatures and other biomarkers. Gal-1 levels were lower in astrocytomas with a better prognosis. These findings suggest that Gal-1 could be a prognostic factor and immune-suppressive biomarker in GBM.
Review
Cell Biology
Gabriele Antonarelli, Valentina Pieri, Francesca Maria Porta, Nicola Fusco, Gaetano Finocchiaro, Giuseppe Curigliano, Carmen Criscitiello
Summary: Various tumors rely on post-translational modifications to promote invasiveness, angiogenesis, and reprogram cellular energetics. Fucosylation, a type of glycosylation, has been linked to immune and hormonal functions as well as tumor development. In breast cancer, fucosylation of the glycan core is associated with poor prognosis and increased metastatic potential. Pre-clinical studies have investigated the molecular mechanisms of core-fucosylation in breast cancer models and its potential as a biomarker for predicting cancer outcomes.